Beam Therapeutics Names First CAR-T Base Editing Development Candidate for the Treatment of T-ALL and Presents New Data at SITC 2020
November 09, 2020 08:15 ET
|
Beam Therapeutics
BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-Cell Acute Lymphoblastic Leukemia First Cell Therapy Featuring Simultaneous Edits to Four...
Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference
October 02, 2020 08:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Pricing of Public Offering of Common Stock
September 30, 2020 20:46 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...
Beam Therapeutics Announces Proposed Public Offering of Common Stock
September 28, 2020 16:18 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines though base-editing, announced today the...
Beam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results
August 12, 2020 06:30 ET
|
Beam Therapeutics
BEAM-101 and BEAM-102 Named as Development Candidates Targeting Distinct Approaches to Treating Sickle Cell Disease Lease Agreement Signed to Build In-house Manufacturing Facility Dedicated to...
Beam Therapeutics to Participate in Upcoming Investor Conferences
July 30, 2020 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
May 26, 2020 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results
May 12, 2020 06:30 ET
|
Beam Therapeutics
Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo Novel HbG-Makassar Program for...
Beam Therapeutics to Present Updated Data Highlighting Base Editing Programs for Sickle Cell Disease at 23rd ASGCT Annual Meeting
April 28, 2020 16:35 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Present First Data Highlighting Base Editing Program for Alpha-1 Antitrypsin Deficiency at 23rd ASGCT Annual Meeting
April 28, 2020 16:35 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...